ArticleJournal of biosciences2017
Rice MYC2 (OsMYC2) modulates light-dependent seedling phenotype, disease defence but not ABA signalling.
Article in Journal of biosciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advances in CRISPR multiplex gene editing to map and modify stress-responsive transcription factor networks for crop improvement.Plant cell reports · 2026Review
- Transcriptome analysis of rice resistant and susceptible near-isogenic lines in response to infection byFrontiers in plant science · 2025Article
- Article
- MKKK20 works as an upstream triple-kinase of MKK3-MPK6-MYC2 module in Arabidopsis seedling development.iScience · 2023Article
- Key Genes in the JAZ Signaling Pathway Are Up-Regulated Faster and More Abundantly in Caterpillar-Resistant Maize.Journal of chemical ecology · 2022Article
- Genome-wide analysis ofFrontiers in plant science · 2022Article
- Jasmonates-the Master Regulator of Rice Development, Adaptation and Defense.Plants (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arabidopsis MYC2 (AtMYC2) is a bHLH class transcription factor that mediates light-dependent seedling development, disease defence, JA and ABA signalling. AtMYC2 gene modulates hypocotyl elongation and expression of chlorophyll A/B binding protein 1 (CAB1) and rubisco small subunit protein1 (RBCS1) under blue light. The atmyc2 mutants are resistant against virulent bacterial pathogens. MYC2 orthologues from several crop plants have been characterized. The rice gene Os10g42430 has been referred earlier as OsMYC2 and has been shown to promote expression of JA-inducible genes. However, the role of OsMYC2 in seedling development under ABA, dark or light of specific wavelengths was not known. It was also not known whether OsMYC2 complements AtMYC2 function in Arabidopsis. We show here that expression of OsMYC2 in the atmyc2 mutant of Arabidopsis complements the blue-light-mediated defects in hypocotyl elongation and expression of CAB1 and RBCS1. We generated multiple transgenic rice lines for over-expression and RNAi-mediated suppression of OsMYC2. In agreement with AtMYC2 function, OsMYC2 over-expression and RNAi lines showed enhanced and suppressed seedling growth compared to WT plants respectively under blue light, and showed little effect under white light or dark. In agreement with the negative regulatory role of AtMYC2 in disease defence, the RNAi lines showed enhanced resistance against bacterial pathogen Xanthomonas oryzae pv oryzae. However, in contrast to AtMYC2 function, OsMYC2 influences seedling development under red light and show no effect in ABA-mediated seed germination. Thus, the results suggest evolutionarily conserved as well as the distinct role of OsMYC2 in comparison with AtMYC2.
Indexed as
Identifiers
29358563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.